Fennec Pharmaceuticals Inc Stock Price, News & Analysis

Fennec Pharmaceuticals (NASDAQ: FENC) reported positive topline results from the investigator‑initiated Phase 2/3 STS-J01 study of PEDMARK® in Japan to reduce cisplatin‑induced hearing loss in pediatric and AYA patients.

The primary cohort (n=27, ages 3–18) met its endpoint: hearing loss rates were 24% (ASHA) and 16% (Brock) with PEDMARK®, versus historically reported cisplatin‑only rates of 56% (ASHA) and 63% (Brock). Pharmacokinetics showed no reduction in cisplatin exposure and tumor response rate was approximately 95%. PEDMARK® was well tolerated; no adverse events were attributed to the drug. Fennec plans to pursue registration in Japan and explore partnering or licensing opportunities.

Fennec Pharmaceuticals (NASDAQ: FENC) will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 at 1:00 p.m. ET. The session will be available via live webcast and an archived replay will be posted after the event.

Investors can access the live webcast via the provided webcast link or from the Events page in the Investors section of the company website (www.fennecpharma.com).

Fennec Pharmaceuticals (NASDAQ:FENC) announced it has repurchased and redeemed all outstanding convertible notes held by Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP, leaving the company with no outstanding debt.

The repurchase used proceeds from the company’s underwritten public offering in the U.S. and concurrent private placement in Canada, which closed on November 17–18, 2025. The aggregate repurchase and redemption price was $21,729,455.30 (comprised of $19,476,655.48 principal, $305,134.27 accrued interest, and a $1,947,665.55 redemption fee). The Petrichor notes had carried interest at prime with a 3.5% floor plus a 4.5% margin and were set to mature on August 19, 2027.

Fennec Pharmaceuticals (NASDAQ:FENC) announced on November 18, 2025 the closing of a non‑brokered Canadian offering of common shares to certain institutional shareholders at US$7.50 per share, raising aggregate gross proceeds of US$5,025,000. The offering was made under the listed issuer financing exemption (Part 5A of NI 45‑106) to purchasers in Canada except Quebec, and the issued shares were registered under the Securities Act of 1933 via a prospectus supplement and accompanying prospectus. Because the offering used the listed issuer financing exemption, the issued common shares are not subject to a Canadian hold period. An offering document is available on SEDAR+ and the company website. The press release clarifies the offering was sold solely in Canada and is not an offer in jurisdictions where registration or qualification is required.

Fennec Pharmaceuticals (NASDAQ:FENC) closed an underwritten registered public offering on Nov 17, 2025 of 5,366,667 common shares at $7.50 per share, including full exercise of the underwriters' option. Gross proceeds before fees were approximately $40,250,000. The company intends to use net proceeds to repurchase and redeem certain indebtedness, with remaining funds for working capital and general corporate purposes. Piper Sandler and Craig-Hallum acted as joint book-running managers; H.C. Wainwright and Stephens served as additional managers. The offering was conducted under a registration statement declared effective by the SEC.

Fennec Pharmaceuticals (NASDAQ:FENC; TSX:FRX) announced a non-brokered private offering in Canada of common shares at US$7.50 per share to certain existing institutional shareholders for aggregate gross proceeds of up to US$5,025,000. The offering is expected to close on November 17, 2025, subject to subscription agreements, customary closing conditions and receipt of required approvals including the Toronto Stock Exchange.

The offering will be made under the listed issuer financing exemption (except Quebec) and the company expects to register any shares in the U.S. under the Securities Act via a prospectus supplement. There is no assurance the offering will complete or the amount raised if completed.

Fennec Pharmaceuticals (NASDAQ:FENC) priced an underwritten public offering of 4,666,667 common shares at $7.50 per share, with gross proceeds expected to be approximately $35,000,000 before discounts and expenses.

The underwriters have a 30‑day option to purchase up to an additional 700,000 shares. The offering is expected to close on November 17, 2025, and net proceeds are planned to repay and redeem indebtedness with any remainder for working capital and general corporate purposes.

Fennec Pharmaceuticals (NASDAQ:FENC) announced on November 13, 2025 a proposed underwritten registered public offering of common shares. The company said it will grant the underwriters a 30-day option to purchase up to an additional 15% of the shares sold.

Fennec intends to use net proceeds to repurchase and redeem certain indebtedness, with any remaining proceeds for working capital and general corporate purposes. Piper Sandler and Craig-Hallum are joint book-running managers. The offering will be made under a registration statement declared effective by the SEC and the shares will not be offered in Canada.

Fennec Pharmaceuticals (NASDAQ: FENC) reported Q3 2025 results on November 13, 2025: net product sales $12.5M (≈79% YoY) and the company said it achieved its first positive cash flow from operations, with cash and cash equivalents rising to $21.9M as of September 30, 2025. The company recorded a small loss of $0.6M for the quarter and operating loss of $0.19M. Management highlighted accelerating adoption of PEDMARK across major oncology networks and investigator-led studies in review. Preliminary results from the Japan STS-J01 trial are expected in Q4 2025, with potential pursuit of registration and partnering if data are positive.